Botulinum Toxin Market: Global Industry Analysis and Forecast (2023-2029)

Botulinum Toxin Market was valued at USD 6.54 Billion in 2022, and is expected to reach USD 13.42 Billion by 2029, exhibiting a CAGR of 10.8 % during the forecast period (2023-2029) Botulinum toxins are neurotoxins that attack nerves and cause muscle paralysis. A bacterium known as clostridium botulinum makes these neurotoxins. Healthcare providers use specific bacteria for medical injections. Injections of botulinum toxin block nerve signals to the muscle injected into it. Without a signal, the muscle cannot contract. The result is a reduction in unwanted facial lines or features. Botulinum toxin injections like Botox and Dysport improve the appearance by relaxing the muscles that cause wrinkles. These injections also treat migraines, hyperhidrosis, overactive bladder, and eye problems.Botulinum Toxin MarketTo know about the Research Methodology :- Request Free Sample Report The botulinum toxin market is characterized by the presence of many small and big companies. To increase their market share, market players are taking up various strategies such as new product approvals in different countries. In November 2020, Revance Therapeutics, Inc. announced that the US Food and Drug Administration (FDA) had approved the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection, an investigational neuromodulator product to treat the moderate to severe glabellar (frown) lines. Globally, the increasing demand for modern beauty standards has created a massive growth platform for botulinum toxin products across the world. Furthermore, therapeutic applications for botulinum toxins have opened the doors for growth through the healthcare platform. In 21 October 2020, there are more than 80 ongoing and planned clinical trials related to Botulinum Toxin across different phases of development for various indications, which is expected to positively impact the botulinum toxin market. The high demand for botulinum toxin has led to several product innovations. There is a subsequent rise in the number of product launches worldwide, resulting from the high demand. Thus, increasing research and development activities and regulatory approvals for botulinum toxin products are expected to show significant growth over the forecast period.

Botulinum Toxin Market Dynamics

Increasing Aesthetics Procedures and Use of Botulinum Toxin to Drive Botulinum Toxin Market Growth There is a significant rise in nonsurgical procedures and dermal injectables across the world. Moreover, the expansion of cosmetology clinics and the increase in the number of cosmetology practitioners are expected to drive the botulinum toxin market during the forecast period. In 2019, the total number of cosmetic procedures were performed in India was 643,752, in which total nonsurgical procedures were 249,024, out of which, botulinum toxin procedures were 70,248. Similarly, a total of 4,401,536 botulinum toxin Type A (Botox, Dysport, Xeomin) minimally-invasive cosmetic procedures were performed in the US, in which 4,136,289 were female, and 265,247 were male. In 2020, total revenue of over USD 9 billion spent on aesthetic plastic surgery. Therapeutic uses of BTX include treating diseases such as chronic migraines, muscle spasticity, over-reactive bladder, and hyperhidrosis. The cosmetic and clinical application of BTX offers a comprehensive and in-depth review of aesthetic procedures and medical applications for standalone treatment, as well as combination therapy. Thus, with the rise in the number of aesthetic service providers, practitioners, and plastic surgeons, the number of aesthetic procedures performed in Asia Pacific is increasing, thereby boosting the demand and sales of botulinum toxin, which is contributing to the growth of the Asia Pacific botulinum toxin market. Rising Number of Non-invasive Cosmetic Procedures to Drive the Growth of Botulinum Toxin Market Cosmetic surgery and injectable BTX are among the most popular noninvasive rejuvenation procedures, and each has its unique way of improving facial aesthetics. In 2020, the BTX treatment was the leading noninvasive cosmetic procedure performed in North America. Moreover, in the last decade, a facial rejuvenation procedure was popular among different types of traditional surgeries in the region. The use of BTX Type A (BoNTA) in cosmetic facial treatments helps improve the aesthetics of the upper and lower face. Thus, the increasing popularity of noninvasive cosmetic procedures is triggering the demand for botulinum toxin in North America. Noninvasive cosmetic treatments have gained popularity in recent years due to minimal downtime, no scarring, low cost, greater accuracy, and fewer complications compared to open procedures. In addition, noninvasive treatments are gaining importance due to lower post-treatment downtime. Moreover, several manufacturers are working on offering more advanced noninvasive cosmetic treatment products. Therefore, the rising awareness about noninvasive cosmetic procedures and the increasing availability of user-friendly and technologically advanced noninvasive cosmetic treatment products are boosting the growth of the Asia Pacific botulinum toxin market. Adverse Effects Associated with Botulinum Toxin to Hamper the Growth of Botulinum Toxin Market The demand for botulinum toxin has been increasing for many years, thanks to its use for aesthetic purposes, to rejuvenate the face and selected areas of the body. However, as botulinum toxin usage is expanding, there are increasing complications related to these procedures that have also been increasing with time. Botox's side effects include erythema, bleeding, swelling, and pain at the injection sites, among others. In addition, patients who undergo Botox injections to treat bunny lines (periorbital) or crow's feet may experience strabismus caused by Botox's injection and local diffusion of Botox. Although botulinum toxin is generally considered safe, its widespread use and the constantly expanded indications raise safety issues. Even in the hands of an experienced person, various complications occur. Fortunately, most of the complications associated with botulinum toxin are allergic reactions, such as rash, neck and back pain, difficulty swallowing, shortness of breath, and nausea. These allergic reactions are hindering the adoption of neurotoxins in therapeutics and cosmetic applications. Other adverse effects include muscle soreness, headaches, light-headedness, fever, chills, hypertension, weakness, diarrhea, and abdominal pain. Muscular weakness, which is the predominant and desirable effect of botulinum toxin injection, also may be considered an adverse effect when weakness occurs in an unintended area or is greater than intended. However, due to the fear of all these side effects stated above, a few of the patients still do not undergo these procedures and treatments, which restrains the growth of the botulinum toxin market.

Botulinum Toxin Market Segment Analysis

Based on Product, Botulinum Toxin Type A dominated the botulinum toxin market in 2022. Botulinum Toxin Type A injections are among the most widely used cosmetic procedures for treating the wrinkles on the face (facial lines) generally caused due to habitual facial muscle contractions. Some of the commonly known injections are Botox, Dysport, Xeomin, and Jeuveau. It is also used in medicines for treating various medical conditions, such as muscle spasms and migraines. For instance, Boucouture (Brand name: Xeomin), developed by Merz Pharmaceuticals, is used to treat blepharospasm and cervical dystonia. Thus, its growing use for medical purposes and the growing number of cosmetic procedures utilizing type A is expected to raise the demand for the botulinum toxin type A injections in the botulinum toxin market. Based on Application, Therapeutic held the largest botulinum toxin market share in 2022. Dystonia is expected to dominate the therapeutic application segment during the forecast period. Several regulatory authorities, such as the US Food and Drug Administration (FDA) and the European Medicines Agency, have approved botulinum toxin injections for the treatment of blepharospasm and cervical dystonia. Several companies are involved in launching products for the treatment of dystonia conditions. Thus, the rising investment by private players in the pharmaceutical sector and the substantial increase in the R&D of novel therapeutics are driving the botulinum toxin market growth. Thanks to the aforementioned factors, the dystonia segment is expected to witness a significant growth during the forecast period.

Regional Insights

North America region dominated the botulinum toxin market in 2022. The growth of the North American botulinum toxin market is due to the highly conscious and economically stable population and a comparatively higher number of interventions in the region. The US holds the largest share of the North American botulinum toxin market. The US is expected to be the largest market for the aesthetics owing to several factors such as rising aesthetic procedures, and growing development of non-invasive aesthetic procedures. Around 1.7 million botulinum toxin procedures were performed in the US in 2019. Botulinum toxin injections to treat facial wrinkles are the country's most commonly performed cosmetic procedures. US citizens are opting for non-invasive aesthetic treatments to minimize facial wrinkles and improve their appearance. Botulinum toxin injection used for treating facial wrinkles is the most performed cosmetic procedure in the United States and one of the most common entry-level procedures for clinicians looking to incorporate aesthetic treatments into their practice. The treatment of frown lines and crow's feet approved by the US Food and Drug Administration-approved cosmetic indications and horizontal forehead wrinkles provide predictable results, have few side effects, and high patient satisfaction. Commercial forms are marketed under Botox Cosmetic/Vistabel by Allergan, Dysport/Azzalure by Galderma and Ipsen, Xeomin/Bocouture by Merz, and in the US only Jeuveau by Evolus manufactured by Daewoong. The US FDA has approved Botox Cosmetic for people aged between 18-65. Asia Pacific botulinum toxin market is expected to grow at a highest CAGR during the forecast period, thanks to the large population countries such as China and India, increasing focus of market players on this region, and introduction of new products or therapies in the country. Notably, people between the ages of 40 and 49 years showed the highest prevalence of migraine. Botulinum toxin is effective in reducing the frequency of headaches and their severity in patients with chronic migraine. In 2017, the prevalence rate of migraine in Japan falls in the range of approx. 8% to 14%. The number of people suffering from headache or migraine has been rising every year. Thus, owing to the high rate of prevalence of migraine among the people, the demand for botulinum toxin in the countries is expected to increase. Moreover, rising incidence of skin rejuvenation, growing awareness of cosmetic procedures to improve aesthetic appeal, increase in healthcare expenditure and availability of technologically advancements in aesthetics products helps to boost the growth of the Asia Pacific botulinum toxin market.

Botulinum Toxin Market Scope: Inquire before buying

Botulinum Toxin Market
Report Coverage Details
Base Year: 2022 Forecast Period: 2023-2029
Historical Data: 2018 to 2022 Market Size in 2022: US 6.54 Bn.
Forecast Period 2023 to 2029 CAGR: 10.8 % Market Size in 2029: US 13.42 Bn.
Segments Covered: by Product Botulinum Toxin Type A Botox Dysport Xeomin Others Botulinum Toxin Type B
by Application Therapeutic Chronic Migraine Overactive Bladder Cervical Dystonia Spasticity Others Aesthetic Glabellar Lines Crow’s Feet Forehead Lines Others
by End-Use Hospitals Dermatology Clinics Spas & Cosmetic Centers
by Region North America Europe Asia Pacific MEA South America

Key Players are:

1. AbbVie Inc. (Allergan) 2. Merz Pharma GmbH & Co. KGaA 3. Evolus, Inc. 4. Revance Therapeutics Inc. 5. HUGEL, Inc. 6. Ipsen Pharma 7. US WorldMeds LLC 8. Medytox 9. Eisai 10. Hugh Source International 11. Galderma 12. Daewoong Pharmaceuticals 13. Allergen Inc. 14. Metabiologics Inc. 15. Lanzhou Institute of Biological Products Frequently Asked Questions: 1] What is the growth rate of the Global Botulinum Toxin Market? Ans. The Global Botulinum Toxin Market is growing at a significant rate of 10.8 % during the forecast period. 2] Which region is expected to have the highest growth rate in the Global Botulinum Toxin Market? Ans. The North America region is expected to hold the highest growth rate in the Botulinum Toxin Market during the forecast period. 3] What is the market size of the Global Botulinum Toxin Market by 2029? Ans. The market size of the Botulinum Toxin Market by 2029 is expected to reach USD 13.42 Bn. 4] What are the major key players of the Global Botulinum Toxin Market? Ans. The major key players of the Global Botulinum Toxin Market are AbbVie Inc. (Allergan), Merz Pharma GmbH & Co. KGaA, Evolus, Inc., Revance Therapeutics Inc., HUGEL, Inc., and Ipsen Pharma. 5] What factors are driving the growth of the Global Botulinum Toxin Market? Ans. Increasing demand for aesthetic procedures and growing research and development initiatives to expand therapeutic applications of botulinum toxin are the major factors expected to drive the Global Botulinum Toxin Market during the forecast period.
1. Botulinum Toxin Market: Research Methodology 2. Botulinum Toxin Market Introduction 2.1. Study Assumption and Market Definition 2.2. Scope of the Study 2.3. Executive Summary 3. Botulinum Toxin Market: Qualitative Analysis 3.1. Technologies used in producing Botulinum Toxin 4. Botulinum Toxin Market: Dynamics 4.1. Botulinum Toxin Market Trends by Region 4.1.1. North America Botulinum Toxin Market Trends 4.1.2. Europe Botulinum Toxin Market Trends 4.1.3. Asia Pacific Botulinum Toxin Market Trends 4.1.4. Middle East and Africa Botulinum Toxin Market Trends 4.1.5. South America Botulinum Toxin Market Trends 4.2. Botulinum Toxin Market Dynamics by Region 4.2.1. North America 4.2.1.1. North America Botulinum Toxin Market Drivers 4.2.1.2. North America Botulinum Toxin Market Restraints 4.2.1.3. North America Botulinum Toxin Market Opportunities 4.2.1.4. North America Botulinum Toxin Market Challenges 4.2.2. Europe 4.2.2.1. Europe Botulinum Toxin Market Drivers 4.2.2.2. Europe Botulinum Toxin Market Restraints 4.2.2.3. Europe Botulinum Toxin Market Opportunities 4.2.2.4. Europe Botulinum Toxin Market Challenges 4.2.3. Asia Pacific 4.2.3.1. Asia Pacific Botulinum Toxin Market Drivers 4.2.3.2. Asia Pacific Botulinum Toxin Market Restraints 4.2.3.3. Asia Pacific Botulinum Toxin Market Opportunities 4.2.3.4. Asia Pacific Botulinum Toxin Market Challenges 4.2.4. Middle East and Africa 4.2.4.1. Middle East and Africa Botulinum Toxin Market Drivers 4.2.4.2. Middle East and Africa Botulinum Toxin Market Restraints 4.2.4.3. Middle East and Africa Botulinum Toxin Market Opportunities 4.2.4.4. Middle East and Africa Botulinum Toxin Market Challenges 4.2.5. South America 4.2.5.1. South America Botulinum Toxin Market Drivers 4.2.5.2. South America Botulinum Toxin Market Restraints 4.2.5.3. South America Botulinum Toxin Market Opportunities 4.2.5.4. South America Botulinum Toxin Market Challenges 4.3. PORTER’s Five Forces Analysis 4.4. PESTLE Analysis 4.5. Regulatory Landscape by Region 4.5.1. North America 4.5.2. Europe 4.5.3. Asia Pacific 4.5.4. Middle East and Africa 4.5.5. South America 4.6. Key Opinion Leader Analysis For Industry 4.7. Analysis of Government Schemes and Initiatives Industry 4.8. The Global Pandemic Impact on Botulinum Toxin Market 5. Botulinum Toxin Market: Global Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030) 5.1. Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 5.1.1. Botulinum Toxin Type A 5.1.1.1. Botox 5.1.1.2. Dysport 5.1.1.3. Xeomin 5.1.1.4. Others 5.1.2. Botulinum Toxin Type B 5.2. Botulinum Toxin Market Size and Forecast, by Application (2023-2030) 5.2.1. Therapeutic 5.2.1.1. Chronic Migraine 5.2.1.2. Overactive Bladder 5.2.1.3. Cervical Dystonia 5.2.1.4. Spasticity 5.2.1.5. Others 5.2.2. Aesthetic 5.2.3. Glabellar Lines 5.2.4. Crow’s Feet 5.2.5. Forehead Lines 5.2.6. Others 5.3. Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 5.3.1. Hospitals 5.3.2. Dermatology Clinics 5.3.3. Spas & Cosmetic Centers 5.4. Botulinum Toxin Market Size and Forecast, By Region (2023-2030) 5.4.1. North America 5.4.2. Europe 5.4.3. Asia Pacific 5.4.4. Middle East and Africa 5.4.5. South America 6. North America Botulinum Toxin Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030) 6.1. North America Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 6.1.1. Botulinum Toxin Type A 6.1.1.1. Botox 6.1.1.2. Dysport 6.1.1.3. Xeomin 6.1.1.4. Others 6.1.2. Botulinum Toxin Type B 6.2. North America Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 6.2.1. Therapeutic 6.2.1.1. Chronic Migraine 6.2.1.2. Overactive Bladder 6.2.1.3. Cervical Dystonia 6.2.1.4. Spasticity 6.2.1.5. Others 6.2.2. Aesthetic 6.2.3. Glabellar Lines 6.2.4. Crow’s Feet 6.2.5. Forehead Lines 6.2.6. Others 6.3. North America Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 6.3.1. Hospitals 6.3.2. Dermatology Clinics 6.3.3. Spas & Cosmetic Centers 6.4. North America Botulinum Toxin Market Size and Forecast, by Country (2023-2030) 6.4.1. United States 6.4.1.1. United States Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 6.4.1.1.1. Botulinum Toxin Type A 6.4.1.1.1.1. Botox 6.4.1.1.1.2. Dysport 6.4.1.1.1.3. Xeomin 6.4.1.1.1.4. Others 6.4.1.1.2. Botulinum Toxin Type B 6.4.1.2. United States Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 6.4.1.2.1. Therapeutic 6.4.1.2.1.1. Chronic Migraine 6.4.1.2.1.2. Overactive Bladder 6.4.1.2.1.3. Cervical Dystonia 6.4.1.2.1.4. Spasticity 6.4.1.2.1.5. Others 6.4.1.2.2. Aesthetic 6.4.1.2.3. Glabellar Lines 6.4.1.2.4. Crow’s Feet 6.4.1.2.5. Forehead Lines 6.4.1.2.6. Others 6.4.1.3. United States Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 6.4.1.3.1. Hospitals 6.4.1.3.2. Dermatology Clinics 6.4.1.3.3. Spas & Cosmetic Centers 6.4.2. Canada 6.4.2.1. Canada Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 6.4.2.1.1. Botulinum Toxin Type A 6.4.2.1.1.1. Botox 6.4.2.1.1.2. Dysport 6.4.2.1.1.3. Xeomin 6.4.2.1.1.4. Others 6.4.2.1.2. Botulinum Toxin Type B 6.4.2.2. Canada Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 6.4.2.2.1. Therapeutic 6.4.2.2.1.1. Chronic Migraine 6.4.2.2.1.2. Overactive Bladder 6.4.2.2.1.3. Cervical Dystonia 6.4.2.2.1.4. Spasticity 6.4.2.2.1.5. Others 6.4.2.2.2. Aesthetic 6.4.2.2.3. Glabellar Lines 6.4.2.2.4. Crow’s Feet 6.4.2.2.5. Forehead Lines 6.4.2.2.6. Others 6.4.2.3. Canada Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 6.4.2.3.1. Hospitals 6.4.2.3.2. Dermatology Clinics 6.4.2.3.3. Spas & Cosmetic Centers 6.4.3. Mexico 6.4.3.1. Mexico Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 6.4.3.1.1. Botulinum Toxin Type A 6.4.3.1.1.1. Botox 6.4.3.1.1.2. Dysport 6.4.3.1.1.3. Xeomin 6.4.3.1.1.4. Others 6.4.3.1.2. Botulinum Toxin Type B 6.4.3.2. Mexico Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 6.4.3.2.1. Therapeutic 6.4.3.2.1.1. Chronic Migraine 6.4.3.2.1.2. Overactive Bladder 6.4.3.2.1.3. Cervical Dystonia 6.4.3.2.1.4. Spasticity 6.4.3.2.1.5. Others 6.4.3.2.2. Aesthetic 6.4.3.2.3. Glabellar Lines 6.4.3.2.4. Crow’s Feet 6.4.3.2.5. Forehead Lines 6.4.3.2.6. Others 6.4.3.3. Mexico Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 6.4.3.3.1. Hospitals 6.4.3.3.2. Dermatology Clinics 6.4.3.3.3. Spas & Cosmetic Centers 7. Europe Botulinum Toxin Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030) 7.1. Europe Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 7.2. Europe Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 7.3. Europe Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 7.4. Europe Botulinum Toxin Market Size and Forecast, by Country (2023-2030) 7.4.1. United Kingdom 7.4.1.1. United Kingdom Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 7.4.1.2. United Kingdom Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 7.4.1.3. United Kingdom Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 7.4.2. France 7.4.2.1. France Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 7.4.2.2. France Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 7.4.2.3. France Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 7.4.3. Germany 7.4.3.1. Germany Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 7.4.3.2. Germany Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 7.4.3.3. Germany Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 7.4.4. Italy 7.4.4.1. Italy Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 7.4.4.2. Italy Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 7.4.4.3. Italy Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 7.4.5. Spain 7.4.5.1. Spain Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 7.4.5.2. Spain Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 7.4.5.3. Spain Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 7.4.6. Sweden 7.4.6.1. Sweden Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 7.4.6.2. Sweden Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 7.4.6.3. Sweden Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 7.4.7. Austria 7.4.7.1. Austria Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 7.4.7.2. Austria Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 7.4.7.3. Austria Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 7.4.8. Rest of Europe 7.4.8.1. Rest of Europe Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 7.4.8.2. Rest of Europe Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 7.4.8.3. Rest of Europe Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 8. Asia Pacific Botulinum Toxin Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030) 8.1. Asia Pacific Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 8.2. Asia Pacific Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 8.3. Asia Pacific Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 8.4. Asia Pacific Botulinum Toxin Market Size and Forecast, by Country (2023-2030) 8.4.1. China 8.4.1.1. China Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 8.4.1.2. China Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 8.4.1.3. China Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 8.4.2. S Korea 8.4.2.1. S Korea Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 8.4.2.2. S Korea Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 8.4.2.3. S Korea Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 8.4.3. Japan 8.4.3.1. Japan Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 8.4.3.2. Japan Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 8.4.3.3. Japan Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 8.4.4. India 8.4.4.1. India Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 8.4.4.2. India Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 8.4.4.3. India Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 8.4.5. Australia 8.4.5.1. Australia Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 8.4.5.2. Australia Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 8.4.5.3. Australia Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 8.4.6. Indonesia 8.4.6.1. Indonesia Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 8.4.6.2. Indonesia Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 8.4.6.3. Indonesia Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 8.4.7. Malaysia 8.4.7.1. Malaysia Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 8.4.7.2. Malaysia Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 8.4.7.3. Malaysia Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 8.4.8. Vietnam 8.4.8.1. Vietnam Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 8.4.8.2. Vietnam Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 8.4.8.3. Vietnam Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 8.4.9. Taiwan 8.4.9.1. Taiwan Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 8.4.9.2. Taiwan Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 8.4.9.3. Taiwan Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 8.4.10. Rest of Asia Pacific 8.4.10.1. Rest of Asia Pacific Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 8.4.10.2. Rest of Asia Pacific Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 8.4.10.3. Rest of Asia Pacific Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 9. Middle East and Africa Botulinum Toxin Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030 9.1. Middle East and Africa Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 9.2. Middle East and Africa Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 9.3. Middle East and Africa Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 9.4. Middle East and Africa Botulinum Toxin Market Size and Forecast, by Country (2023-2030) 9.4.1. South Africa 9.4.1.1. South Africa Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 9.4.1.2. South Africa Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 9.4.1.3. South Africa Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 9.4.2. GCC 9.4.2.1. GCC Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 9.4.2.2. GCC Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 9.4.2.3. GCC Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 9.4.3. Nigeria 9.4.3.1. Nigeria Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 9.4.3.2. Nigeria Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 9.4.3.3. Nigeria Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 9.4.4. Rest of ME&A 9.4.4.1. Rest of ME&A Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 9.4.4.2. Rest of ME&A Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 9.4.4.3. Rest of ME&A Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 10. South America Botulinum Toxin Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030 10.1. South America Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 10.2. South America Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 10.3. South America Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 10.4. South America Botulinum Toxin Market Size and Forecast, by Country (2023-2030) 10.4.1. Brazil 10.4.1.1. Brazil Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 10.4.1.2. Brazil Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 10.4.1.3. Brazil Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 10.4.2. Argentina 10.4.2.1. Argentina Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 10.4.2.2. Argentina Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 10.4.2.3. Argentina Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 10.4.3. Rest Of South America 10.4.3.1. Rest Of South America Botulinum Toxin Market Size and Forecast, By Product (2023-2030) 10.4.3.2. Rest Of South America Botulinum Toxin Market Size and Forecast, By Application (2023-2030) 10.4.3.3. Rest Of South America Botulinum Toxin Market Size and Forecast, By End-Use (2023-2030) 11. Global Botulinum Toxin Market: Competitive Landscape 11.1. MMR Competition Matrix 11.2. Competitive Landscape 11.3. Key Players Benchmarking 11.3.1. Company Name 11.3.2. Service Segment 11.3.3. End-user Segment 11.3.4. Revenue (2023) 11.3.5. Company Locations 11.4. Leading Botulinum Toxin Market Companies, by Market Capitalization 11.5. Market Structure 11.5.1. Market Leaders 11.5.2. Market Followers 11.5.3. Emerging Players 11.6. Mergers and Acquisitions Details 12. Company Profile: Key Players 12.1. AbbVie Inc. (Allergan) 12.1.1. Company Overview 12.1.2. Business Portfolio 12.1.3. Financial Overview 12.1.4. SWOT Analysis 12.1.5. Strategic Analysis 12.1.6. Recent Developments 12.2. Merz Pharma GmbH & Co. KGaA 12.3. Evolus, Inc. 12.4. Revance Therapeutics Inc. 12.5. HUGEL, Inc. 12.6. Ipsen Pharma 12.7. US WorldMeds LLC 12.8. Medytox 12.9. Eisai 12.10. Hugh Source International 12.11. Galderma 12.12. Daewoong Pharmaceuticals 12.13. Allergen Inc. 12.14. Metabiologics Inc. 12.15. Lanzhou Institute of Biological Products 13. Key Findings 14. Industry Recommendations
  • INQUIRE BEFORE BUYING